MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Go back to MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.20 +0.15 (4.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.05 | 52 Week High | $2.51 | |||
| Open | $3.03 | 52 Week Low | $0.41 | |||
| Day High | $3.21 | P/E | N/A | |||
| Day Low | $3.01 | EPS | $-0.64 | |||
| Volume | 3,254,376 | |||||



